Evidence map›Paper›PMID 15727582›Full record

Trial reportAllergy2005

Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial.

M Viljanen, E Savilahti, T Haahtela, K Juntunen-Backman, R Korpela, T Poussa, T Tuure, M Kuitunen

2 registry-linked trialsAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Allergy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 102 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 10 pooled it
44.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00378300 nawithdrawnnot on this mapstarted 2007, after this paper: background citation

Probiotics Ameliorate Atopic Dermatitis by Induction of T Regulatory Cells

TypeinterventionalSponsorUniversity of California, Los AngelesRan2007 to 2008Enrolled0ConditionsAtopic DermatitisArmsOral Probiotics
NCT00445120 phase2 / phase3completednot on this mapstarted 2007, after this paper: background citation

Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Lactobacillus Rhamnosus GG Treatment in Preventing Vernal Keratoconjunctivitis VKC) Relapses.

TypeinterventionalSponsorCampus Bio-Medico UniversityRan2007 to 2009Enrolled48ConditionsVernal KeratoconjunctivitisArmsLactobacillus Rhamnosus GG, placebo (sugar)
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 10 syntheses or guidelines pooled it, 479 citations in OpenAlex.

  1. Probiotics in infants for prevention of allergic disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Frontiers in pediatrics · 2021
    Pooled it
  7. Pooled it
  8. Probiotics for treating eczema.The Cochrane database of systematic reviews · 2018
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Effects ofJournal of Korean medical science · 2020
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

M ViljanenThe Skin and Allergy Hospital, University of Helsinki, Helsinki, Finland.
E Savilahti
T Haahtela
K Juntunen-Backman
R Korpela
T Poussa
T Tuure
M Kuitunen
University of Helsinki · FIAllergy and Asthma Federation · FIStatistics Finland · FIValio (Finland) · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProbiotic bacteria are suggested to reduce symptoms of the atopic eczema/dermatitis syndrome (AEDS) in food-allergic infants. We aimed to investigate whether probiotic bacteria have any beneficial effect on AEDS.

methodsFollow-up of severity of AEDS by the Severity Scoring of Atopic Dermatitis (SCORAD) index in 230 infants with suspected cow's milk allergy (CMA) receiving, in a randomized double-blinded manner, concomitant with elimination diet and skin treatment, Lactobacillus GG (LGG), a mixture of four probiotic strains, or placebo for 4 weeks. Four weeks after the treatment, CMA was diagnosed with a double-blind placebo-controlled (DBPC) milk challenge in 120 infants.

resultsIn the whole group, mean SCORAD (at baseline 32.5) decreased by 65%, but with no differences between treatment groups immediately or 4 weeks after the treatment. No treatment differences were observed in infants with CMA either. In IgE-sensitized infants, however, the LGG group showed a greater reduction in SCORAD than did the placebo group, -26.1 vs-19.8 (P=0.036), from baseline to 4 weeks after the treatment. Exclusion of infants who had received antibiotics during the study reinforced the findings in the IgE-sensitized subgroup.

conclusionTreatment with LGG may alleviate AEDS symptoms in IgE-sensitized infants but not in non-IgE-sensitized infants.

Indexed as

BacteriaColony Count, MicrobialDermatitis, AtopicDouble-Blind MethodFecesFemaleHumansImmunoglobulin EInfantLactobacillusMaleMilk HypersensitivityProbioticsSeverity of Illness IndexSyndromeImmunoglobulin E

Identifiers

PMID15727582
OpenAlexW2165898725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.